Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS

Record History

See every version on ClinicalTrials.gov ↗

1. Notable Mar 25, 2026 Primary completion pushed from Mar 2027 to Sep 30, 2027v3 Show 8 more changesShow less

   • Primary endpoint(s) modified
   • Enrollment reduced: 40 → 20 participants
   • Start date: Feb 4, 2026 to Apr 1, 2026
   • Study completion pushed from Mar 1, 2027 to Sep 30, 2027
   • Interventions: Apixaban 2.5 MG (Drug), subcutaneous Low Molecular Weight Heparin (Drug) to Apixaban 2.5 MG (Drug)
   • Eligibility criteria expanded, about 53 words
   • Secondary endpoints: 2 to 1
   • Study description shortened, about 85 words
2. Notable Mar 18, 2026 Primary completion date: Mar 1, 2026 to Mar 2027v2 Show 9 more changesShow less

   • Start date: Mar 4, 2025 to Feb 4, 2026
   • Primary endpoints: 1 to 3
   • Trial status: Completed to Recruiting
   • Study completion date: Mar 1, 2026 to Mar 1, 2027
   • Eligibility criteria expanded, about 52 words
   • Secondary endpoints revised (2)
   • Study description shortened, about 35 words
   • Site details revised
   • Study title expanded, about 1 word
3. Minor Mar 4, 2026 Study First Submitted

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.